DOSES STUDIED
Semaglutide dosage, as the trials and the label actually documented it.
The titration ladders, the oral schedule, and the route differences — reported in the third person, exactly as studied. Never a dose to follow.
The short version
This page reports the semaglutide dosage as it appears in the published trials and the approved label — not as a recommendation for anyone. The big picture: doses start low and step up over weeks, because raising the dose slowly is how the trials kept nausea manageable. For weight management, the studied subcutaneous schedule climbs from 0.25 mg to a 2.4 mg weekly maintenance dose over about four months. For diabetes, the maintenance dose is usually lower. There is also a once-daily pill that must be taken on an empty stomach. Because the drug lasts about a week in the body, it is dosed weekly (shot) or daily (pill). Nothing here tells you what to take — talk to a clinician for that.
Semaglutide dose: the subcutaneous titration ladder
The studied semaglutide dose escalates deliberately. For chronic weight management, the documented subcutaneous schedule is 0.25 mg once weekly for weeks 1-4, then 0.5 mg (weeks 5-8), 1.0 mg (weeks 9-12), 1.7 mg (weeks 13-16), and 2.4 mg once-weekly maintenance — the dose used in STEP 1 to reach -14.9% body weight [1]. For type 2 diabetes, the documented schedule is 0.25 mg for initiation, then 0.5 mg, then 1.0 mg maintenance, with up to 2.0 mg studied in SUSTAIN FORTE, which gave greater HbA1c lowering than 1.0 mg [9]. The slow climb is not arbitrary — a pooled STEP analysis tied most gastrointestinal events to the titration period and found them mostly mild-to-moderate and transient [13].
Semaglutide dosage across indications
The semaglutide dosage differs by purpose. Weight management uses the higher 2.4 mg weekly maintenance dose [1]; diabetes commonly uses 0.5-1.0 mg weekly, with 2.0 mg available [9]. Investigational and oral-obesity programs explored higher doses still — oral 25 mg and 50 mg once daily in the OASIS/PIONEER PLUS programs, and a 7.2 mg once-weekly subcutaneous dose in high-dose obesity research [10]. These are research and label figures, reported here in the third person, not a personalized dose.
Semaglutide injection: the once-weekly route
The semaglutide injection is a once-weekly subcutaneous shot — the route used across STEP, SUSTAIN, SELECT and FLOW [1][3][6]. Weekly dosing works because the elimination half-life is approximately one week, so drug levels stay steady between shots and persist for about five weeks after the last one [11]. Commercial pre-filled pens are typically stored refrigerated (2-8 C) before first use and may then be kept at room temperature (up to 30 C) for a defined in-use period (commonly cited as up to 56 days) per the label.
Oral semaglutide: the once-daily tablet
Oral semaglutide is a once-daily tablet co-formulated with an absorption enhancer called SNAC. The documented schedule is 3 mg daily for 30 days, then 7 mg, then 14 mg daily, taken on an empty stomach 30 minutes before the first food, drink or other medication, with no more than about 120 mL of water [11]. The reason for the strict fasting is pharmacology, not fussiness: oral bioavailability is only ~0.4-1% even with SNAC, so food or extra water in the stomach can sharply cut how much is absorbed [20]. PIONEER trials established oral efficacy in diabetes, and OASIS extended higher oral doses to obesity [10].
Why titration is slow, in plain terms
The deliberate, weeks-long climb from a small starting dose to maintenance is the single most consistent feature of how semaglutide was studied — and it exists for tolerability, not caution for its own sake. A pooled analysis of the STEP weight-management program found gastrointestinal events were predominantly mild-to-moderate and transient and clustered around the dose-escalation period [13]. In other words, the trials raised the dose slowly precisely so the nausea that the mechanism produces would stay manageable as the body adjusted. The same safety review that documents nausea in roughly one-third of patients frames these effects as the dominant but largely transient tolerability burden [5]. That is why every documented schedule on this page steps up rather than starting at the maintenance dose.
Half-life, washout and drug interactions
The ~1-week half-life shapes more than the dosing interval [11]. It is why label guidance advises stopping well before a planned pregnancy — full clearance takes roughly five weeks, so a washout of about two months is commonly cited [11]. On interactions, a systematic review found GLP-1 receptor agonists generally do not cause clinically significant drug interactions despite slowed gastric emptying, but advised monitoring for narrow-therapeutic-index oral drugs during dose escalation [21]. None of this is guidance to act on — it is the documented pharmacology behind why the schedules look the way they do.